Case analysis of fertility-preserving treatment in female patients with malignant ovarian cancer

The aim of this study was to evaluate the impacts of fertility-preserving surgery and chemotherapy on the fertility and ovarian functions in malignant ovarian cancer. The clinical data of 52 female patients with malignant ovarian cancer and performed fertility-preserving treatment (FPT) in the present hospital between June 2004 and December 2014 were retrospectively analyzed. The 52 cases included 25 cases of germ cell carcinoma (GCC) (48.07%), 12 cases of epithelial ovarian carcinoma (EOC) (23.07%), and 15 cases of borderline carcinoma (28.84%), among which one case recurred (1.92%) and one died (1.92%). Forty-five cases had normal menstruation after the treatment (86.53%), and 16 cases out of the 27 cases with fertility requirement successfully achieved pregnancy (59.26%). FPT in female patients with malignant ovarian cancer was effective and feasible; although chemotherapy might affect ovarian function, it could also be reversed. Ovarian tumor resection or adnexectomy may be the best way for fertility preserving treatments; however, further investigation is warranted.

Ovarian cancer; Fertility-preserving treatment; Surgery; Chemotherapy.

[1] Lozano R., Naghavi M., Foreman K., Lim S., Shibuya K., Aboyans V., et al.: “Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010”. Lancet, 2012, 380, 2095.

[2] Chornokur G., Amankwah E.K., Schildkraut J.M., Phelan C.M.: “Global ovarian cancer health disparities”. Gynecol. Oncol., 2013, 129, 258.

[3] Kurman R.J., Shih IeM.: “The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory”. Am. J. Surg. Pathol., 2010, 34, 433.

[4] Eisenhauer E.L., Abu-Rustum N.R., Sonoda Y., Aghajanian C., Barakat R.R., Chi D.S.: “The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer”. Gynecol. Oncol., 2008, 108, 276.

[5] Fleming G.F., Ronnett B.M., Seidman J., Zaino R.J., Rubin S.C.: “Epithelial ovarian cancer”. In: Barakat R.R., Markman M., Randall M.E., (eds). Principles and practice of gynecologic oncology. Philadelphia: Lippincott Williams & Wilkins, 2009, 763.

[6] Morgan R.J., Alvarez R.D., Armstrong D.K., Burger R.A., Chen L.M., Copeland L., et al.: “Ovarian cancer, version 2.2013”. J. Natl. Compr. Canc. Netw., 2013, 11, 1199.

[7] Feeley K.M., Wells M.: “Precursor lesions of ovarian epithelial malignancy”. Histopathology, 2001, 38, 87.

[8] Colombo N., Peiretti M., Castiglione M.: “Non-epithelial ovarian cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up”. Ann. Oncol., 2009, 20, 24.

[9] del Carmen M.G., Birrer M., Schorge J.O.: “Carcinosarcoma of the ovary: a review of the literature”. Gynecol. Oncol., 2012, 125, 271.

[10] Brown J., Frumovitz M.: “Mucinous tumors of the ovary: current thoughts on diagnosis and management”. Curr. Oncol. Rep., 2014, 16, 389.

[11] Wei W., Dizon D., Vathipadiekal V., Birrer M.J.: “Ovarian cancer: genomic analysis”. Ann. Oncol., 2013, 24, x7.

[12] Mahajan N.: “Fertility preservation in female cancer patients: An overview”. J. Hum. Reprod. Sci., 2015, 8, 3.

[13] Nishio S., Ushijima K., Fukui A., Fujiyoshi N., Kawano K., Komai K., et al.: “Fertility-preserving treatment for patients with malignant germ cell tumors of the ovary”. J. Obstet. Gynaecol. Res., 2006, 32, 416.

[14] Lee S.J., Schover L.R., Partridge A.H., Patrizio P., Wallace W.H., Hagerty K., et al: “American Society of Clinical Oncology recommendations on fertility preservation in cancer patients”. J. Clin. Oncol., 2006, 24, 2917.

[15] Wright J.D., Shah M., Mathew L., Burke W.M., Culhane J., Goldman N., et al.: “Fertility preservation in young women with epithelial ovarine cancer”. Cancer, 2009, 115, 4118.

[16] du Bois A., Heitz F., Harter P.: “Fertility-sparing surgery in ovarian cancer: a systematic review”. Onkologie, 2013, 36, 436.

[17] Ditto A., Martinelli F., Lorusso D., Haeusler E., Carcangiu M., Raspagliesi F.: “Fertility sparing surgery in early stage epithelial ovarian cancer”. J. Gynecol. Oncol., 2014, 25, 320.

[18] Kajiyama H., Mizuno M., Shibata K., Yamamoto E., Kawai M., Nagasaka T., et al.: “Recurrence-predicting prognostic factors for patients with early-stage epithelial ovarian cancer undergoing fertility-sparing surgery: a multi-institutional study”. Eur. J. Obstet. Gynecol. Reprod. Biol., 2014, 175, 97.

[19] Vasconcelos I., de Sousa Mendes M.: “Conservative surgery in ovarian borderline tumours: a meta-analysis with emphasis on recurrence risk”. Eur. J. Cancer., 2015, 51, 620.

[20] Kajiyama H., Shibata K., Mizuno M., Umezu T., Suzuki S., Nawa A., et al.: “Long-term survival of young women receiving fertility-sparing surgery for ovarian cancer in comparison with those undergoing radical surgery”. Br. J. Cancer., 2011, 105, 1288.

[21] Donnez J., Munschke A., Berliere M., Pirard C., Jadoul P., Smets M., et al.: “Safety of conservative management and fertility outcome in women with borderline carcinomas of the ovary”. Fertil. Steril., 2003, 79, 1216.

[22] Fotopoulou C., Braicu I., Sehouli J.: “Fertility-sparing surgery in early epithelial ovarian cancer: a viable option?” Obstet. Gynecol. Int., 2012, 2012, 238061.

[23] Makarewicz H., Emerich J., Olszewski J., Klasa-Mazurkiewicz D.: “Pregnancy and delivery after conservative treatment of borderline ovarine tumer with FIGO stage IIIC-a case report”. Ginekol. Pol., 2002, 73, 225.

[24] Oven Ustaalioglu B.B., Bilici A., Kefeli U., Seker M., Salepci T., Unal O., Gumus M.: “A retrospective analysis of women’s chances to become pregnant after completion of chemotherapy: a single center experience”. J. BUON., 2011, 16, 349.

[25] Fauvet R, Boccara J, Dufournet C, David-Montefiore E, Poncelet C, Daraï E: “Restaging surgery forwomen with borderline ovarian tumors”. Cancer, 2004, 100, 1145.

[26] Seltzer V., Drukker B.H., Gillespie B.W., Gossfeld L.M., Grigsby P.W., Harvey H.A., et al.: “NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer”. JAMA., 1995, 273, 491.

[27] Billmire D., Vinocur C., Rescorla F., Cushing B., London W., Schlatter M., et al.: “Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: an intergroup study”. J. Pediatric. Surg., 2004, 39, 424.